Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cofrogliptin vs metformin in treatment-naïve type 2 diabetes mellitus
ChiCTR2500105068Phase 4Not yet recruiting
- Sponsor
- Changhai Hospital
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cofrogliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Changhai Hospital. Primary endpoint: HbA1c goal attainment at 12 weeks. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
cofrogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2500105068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105068.